🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study

RecruitingNAAges 18 Years - 70 YearsAllUniversity of Melbourne
NCT07055542 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Thunderstorm asthma is a recurring public health emergency in South-Eastern Australia which occurs in springtime. The major identified risk factors for thunderstorm asthma is hay fever and allergy to ryegrass pollen. The goal of the CARISTA study is to identify the risk of springtime allergic and thunderstorm asthma in allergic adults living in South-Eastern Australia. To do this the investigators will recruit 530 people who have hay fever and test them for allergy to ryegrass pollen and undertake simple lung function testing. The investigators will ask study participants to complete a customised symptom tracker over the springtime pollen season for 2 consecutive years. The outcome the investigators are looking for is an asthma exacerbation or worsening asthma symptoms. This study will enable the investigators to identify indicators (biomarkers) of severe and moderate asthma exacerbation

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Consenting adults aged 18 to 70 years with seasonal allergic rhinitis willing to undertake: * Lung function testing * Blood sample collection for risk factor identification, -Prospectively logging their symptoms and medications through the springtime season using the CARISTA symptom monitoring platform . - Exclusion Criteria: * Individuals unable to provide informed consent * Individuals who do not suffer from symptoms of seasonal allergic rhinitis * Individuals who do not consent to lung function testing and blood sample collection - Individuals with unstable asthma (FEV1 by spirometry less than 70% predicted), a recent exacerbation or change of asthma preventive medication use (within one month) would be excluded, although re-screening would be permitted after one month, time permitting. * Individuals with severe asthma requiring the use of continuous oral corticosteroids or biological medication for severe asthma. * The presence of any medical illness, such as cardiac disease, pre-existing illness or immunomodulatory therapy that, in the opinion of the Investigators, would compromise participant safety or the derivation of biomarkers during the study.
💊

What it tests

  • Observational
📍

Where

6 sites
Albury-Wodonga Health
Albury, Australia
Eastern Health
Box Hill, Australia
Monash Health
Clayton, Australia
Austin Health
Heidelberg, Australia
The Alfred Hospital
Melbourne, Australia
The Royal Melbourne Hospital
Parkville, Australia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy